Johnson & Johnson (JNJ) Shares Bought by Advisors Capital Management LLC

Advisors Capital Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 76,701 shares of the company’s stock after buying an additional 4,891 shares during the period. Advisors Capital Management LLC’s holdings in Johnson & Johnson were worth $10,147,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the last quarter. Landmark Financial Advisors LLC raised its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Landmark Financial Advisors LLC now owns 1,948 shares of the company’s stock worth $224,000 after buying an additional 10 shares during the last quarter. Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after buying an additional 14 shares during the last quarter. Berson & Corrado Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock worth $353,000 after buying an additional 19 shares during the last quarter. Finally, Cascade Investment Advisors Inc. raised its position in shares of Johnson & Johnson by 0.3% in the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock worth $932,000 after buying an additional 23 shares during the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.

Shares of Johnson & Johnson (JNJ) opened at 133.10 on Friday. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The stock has a 50 day moving average of $133.09 and a 200-day moving average of $126.30. The stock has a market capitalization of $357.24 billion, a P/E ratio of 22.52 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.74 earnings per share. Analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Advisors Capital Management LLC” was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/12/advisors-capital-management-llc-increases-position-in-johnson-johnson-jnj-updated-updated.html.

JNJ has been the topic of several analyst reports. Barclays PLC reaffirmed an “equal weight” rating and set a $130.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research note on Monday, April 17th. BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research note on Wednesday, April 19th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price target for the company in a research note on Monday, April 24th. Jefferies Group LLC reissued a “hold” rating and set a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. Finally, J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $123.64 to $140.00 in a research note on Monday, May 15th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $133.72.

In other news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit